Methods of treating kawasaki disease
AssigneeSeattle Children's Hospital d/b/a Seattle Children's Research Institute
InventorMichael A. Portman
Life of this patent
Estimating the term…
Abstract
The present invention relates to the discovery that etanercept reduces the rate of resistance to intravenous gamma globulin (IVIG) in subjects with acute Kawasaki disease (KD). In certain embodiments, the co-administration of etanercept and IVIG more effectively treats acute KD in subjects older than 12 months than IVIG alone. In other embodiments, the co-administration of etanercept and IVIG ameliorates coronary artery dilation in high risk subjects.
Claims52
A method of treating acute Kawasaki Disease (KD) in a human subject in need thereof, the method comprises administering to the subject a therapeutically effective amount of intravenous gamma globulin (IVIG) and a therapeutically effective amount of etanercept.
A method of reducing or preventing IVIG resistance in a subject being administered IVIG for the treatment of KD, the method comprising administering to the subject a therapeutically effective amount of etanercept.
A method of ameliorating or preventing progression, or promoting regression, of coronary artery dilation in a subject suffering from KD, the method comprising administering to the subject a therapeutically effective amount of etanercept.
Dependencies are inferred from the claim text.